FNP 223
Alternative Names: ASN-120290; ASN-561; ASN-90; FNP-223Latest Information Update: 05 Jul 2024
At a glance
- Originator Asceneuron
- Developer Asceneuron; Ferrer
- Class Neuroprotectants; Small molecules
- Mechanism of Action Hexosaminidase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Progressive supranuclear palsy
Most Recent Events
- 20 Jun 2024 Phase-II clinical trials in Progressive supranuclear palsy in USA (PO) (NCT06355531)
- 12 Apr 2024 Ferrer plans a phase II PROSPER trial for Progressive supranuclear palsy (In the elderly) in April 2024 (PO) (NCT06355531)
- 29 Mar 2024 ASN 90 is still in phase-I development in Progressive-supranuclear-palsy in Switzerland (PO)